| human | Q5 |
| P1153 | Scopus author ID | 15830375100 |
| P4012 | Semantic Scholar author ID | 83321152 |
| P108 | employer | Johns Hopkins School of Medicine | Q858729 |
| P734 | family name | Petri | Q18627533 |
| Petri | Q18627533 | ||
| Petri | Q18627533 | ||
| P735 | given name | Michelle | Q15621047 |
| Michelle | Q15621047 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q49049719 | "Subcortical" cognitive impairment in patients with systemic lupus erythematosus. |
| Q38211487 | 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends |
| Q37131283 | 2013 update: Hopkins lupus cohort |
| Q35086343 | 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort |
| Q47849038 | 3' polymorphisms of ETS1 are associated with different clinical phenotypes in SLE. |
| Q62111836 | 3? polymorphisms of ETS1 are associated with different clinical phenotypes in SLE |
| Q38409092 | A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach |
| Q48588705 | A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires |
| Q73484086 | A TNFR2 3' flanking region polymorphism in systemic lupus erythematosus |
| Q28236839 | A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus |
| Q43772908 | A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus |
| Q39019163 | A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). |
| Q28263690 | A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus |
| Q24629130 | A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus |
| Q34416115 | A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study |
| Q37378350 | A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus |
| Q28254310 | A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus |
| Q56451740 | A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus |
| Q34722499 | A polymorphism in TLR2 is associated with arterial thrombosis in a multiethnic population of patients with systemic lupus erythematosus |
| Q37435526 | A polymorphism within IL21R confers risk for systemic lupus erythematosus |
| Q46534340 | A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans |
| Q34978377 | A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis |
| Q51381212 | A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. |
| Q37260222 | ABIN1 dysfunction as a genetic basis for lupus nephritis |
| Q34233328 | Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics |
| Q35565755 | Aberrant regulation of the integrin very late antigen-4 in systemic lupus erythematosus |
| Q33851587 | Abnormal production of pro- and anti-inflammatory cytokines by lupus monocytes in response to apoptotic cells |
| Q96221671 | Accrual of atherosclerotic vascular events in a multicentre inception SLE cohort |
| Q31145074 | Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort |
| Q44723982 | Accuracy of creatinine clearance in measuring glomerular filtration rate in patients with systemic lupus erythematosus without clinical evidence of renal disease |
| Q28486228 | Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production |
| Q37695854 | Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses |
| Q57711764 | Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology |
| Q45345442 | American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort |
| Q43981301 | An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort |
| Q38474206 | An international cohort study of cancer in systemic lupus erythematosus |
| Q50649613 | An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. |
| Q77880375 | An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus |
| Q37331992 | An update on mortality in systemic lupus erythematosus |
| Q35884207 | Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus |
| Q44355594 | Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus. |
| Q36421501 | Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study |
| Q73109057 | Antenatal detection of intrauterine growth restriction in patients with systemic lupus erythematosus |
| Q46721516 | Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers |
| Q34717540 | Anti-C1q antibodies in systemic lupus erythematosus |
| Q51724933 | Anti-C1q in systemic lupus erythematosus. |
| Q38636787 | Anti-Ro antibodies and neonatal lupus |
| Q46316255 | Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. |
| Q28218219 | Anti-inflammatory and immunosuppressive drugs and reproduction |
| Q45260710 | Antibiotic allergy in systemic lupus erythematosus: a case-control study |
| Q37541229 | Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study |
| Q28290612 | Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women |
| Q71683350 | Antiphospholipid antibodies and retinal vascular disease |
| Q41640016 | Antiphospholipid antibody syndrome: an acquired cause of venous and arterial hypercoagulability. |
| Q46154335 | Aortic valve calcification in systemic lupus erythematosus |
| Q33887814 | Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus |
| Q28217805 | Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals |
| Q73198900 | Assessing disease activity in SLE patients during pregnancy |
| Q37063656 | Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. |
| Q52862110 | Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod. |
| Q46496763 | Associates and predictors of pleurisy or pericarditis in SLE. |
| Q60913120 | Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus |
| Q36842737 | Association of Antibodies to Interferon-Inducible Protein-16 With Markers of More Severe Disease in Primary Sjögren's Syndrome |
| Q35184749 | Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups |
| Q35012624 | Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus |
| Q73613533 | Association of coping responses with fibromyalgia tender points in patients with systemic lupus erythematosus |
| Q36573884 | Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort |
| Q33921170 | Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility |
| Q36054578 | Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis |
| Q34802966 | Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus |
| Q28265206 | Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX |
| Q36360650 | Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus |
| Q51747448 | Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus. |
| Q35525108 | Atherosclerosis in systemic lupus erythematosus |
| Q34338929 | Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus |
| Q36307423 | Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study |
| Q36332517 | Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus |
| Q53047741 | Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. |
| Q34656925 | Autoantibody tests in autoimmune thyroid disease: a case-control study. |
| Q35868721 | Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis |
| Q52684685 | Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. |
| Q35768902 | BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year |
| Q77956670 | Baseline characteristics of a multiethnic lupus cohort: PROFILE |
| Q57332162 | Baseline characteristics of a multiethnic lupus cohort: PROFILE |
| Q57332182 | Baseline characteristics of a multiethnic lupus cohort: PROFILE |
| Q30645037 | Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials |
| Q36094045 | Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response |
| Q45055130 | Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease |
| Q37760766 | Biologics in the treatment of systemic lupus erythematosus |
| Q37613091 | Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus |
| Q40559886 | Breast cancer in systemic lupus |
| Q37602561 | Breast cancer in systemic lupus erythematosus |
| Q40167126 | Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment |
| Q39909645 | Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes |
| Q36897482 | Brief Report: Single-nucleotide polymorphisms in VKORC1 are risk factors for systemic lupus erythematosus in Asians |
| Q44615394 | Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel |
| Q73101140 | C4A deficiency due to a 2 bp insertion is increased in patients with systemic lupus erythematosus |
| Q46149858 | Can women with systemic lupus erythematosus safely use exogenous estrogens? |
| Q46791930 | Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients |
| Q36823763 | Cancer risk in systemic lupus: an updated international multi-centre cohort study |
| Q35189299 | Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report |
| Q36811755 | Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort |
| Q34435380 | Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients |
| Q47556201 | Cerebrovascular Events in Systemic Lupus Erythematosus |
| Q48086630 | Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus |
| Q69229794 | Chronic active hepatitis presenting with rheumatoid nodules and arthritis |
| Q35691674 | Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis |
| Q73198904 | Classification and definition of major flares in SLE clinical trials |
| Q35973810 | Classification criteria for systemic lupus erythematosus: a review |
| Q49475768 | Clinical Outcomes Observed among Biopsy Proven Lupus Nephritis Patients Treated with Mycophenolate Mofetil as First-line Therapy |
| Q35762748 | Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort |
| Q38807174 | Clinical associations of proinflammatory cytokines, oxidative biomarkers and vitamin D levels in systemic lupus erythematosus |
| Q30560952 | Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort |
| Q40858985 | Clinical features of systemic lupus erythematosus |
| Q40651140 | Clinical features of systemic lupus erythematosus. |
| Q40921570 | Clinical features of systemic lupus erythematosus. |
| Q31122937 | Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort |
| Q46792375 | Clinical response to belimumab in academic clinical practices |
| Q51278072 | Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus. |
| Q46803412 | Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index |
| Q34478853 | Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials |
| Q51963212 | Cognitive function in a systemic lupus erythematosus inception cohort. |
| Q43101009 | Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis |
| Q46851436 | Combined oral contraceptives in women with systemic lupus erythematosus |
| Q43531127 | Comparison of different methods of classifying patients with systemic lupus erythematosus |
| Q48164014 | Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies |
| Q37271565 | Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing |
| Q93110379 | Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus |
| Q50978565 | Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus. |
| Q37206907 | Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis |
| Q44589658 | Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices |
| Q36468887 | Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis |
| Q46028181 | Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. |
| Q78108547 | Correlation of serum measures of nitric oxide production with lupus disease activity |
| Q37456307 | Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials |
| Q33368551 | Cyclophosphamide for lupus during pregnancy |
| Q35824515 | Cyclophosphamide: new approaches for systemic lupus erythematosus |
| Q74175875 | Damage in systemic lupus erythematosus and its association with corticosteroids |
| Q38801880 | Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production |
| Q38439759 | Decreased live births in women with systemic lupus erythematosus |
| Q43772904 | Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus |
| Q53281418 | Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. |
| Q67925068 | Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study |
| Q42969082 | Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus |
| Q72576077 | Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjögren's syndrome |
| Q41977234 | Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus |
| Q53568378 | Dermatologic lupus: Hopkins Lupus Cohort. |
| Q33915430 | Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort |
| Q46008611 | Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. |
| Q35229755 | Development and initial validation of a self-assessed lupus organ damage instrument |
| Q40352736 | Development of Biomarker Models to Predict Outcomes in Lupus Nephritis |
| Q38913296 | Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis |
| Q35642120 | Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice |
| Q33491582 | Diagnosis of antiphospholipid antibodies. |
| Q48021905 | Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a screening tool for proteinuria in lupus nephritis. |
| Q77484128 | Diet and systemic lupus erythematosus: from mouse and monkey to woman? |
| Q36708729 | Differences between male and female systemic lupus erythematosus in a multiethnic population |
| Q29417056 | Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production |
| Q39449781 | Diffuse lymphadenopathy as the presenting manifestation of systemic lupus erythematosus |
| Q70787288 | Discoid lupus erythematosus-like lesions and stomatitis in female carriers of X-linked chronic granulomatous disease |
| Q36171764 | Disease activity assessment in SLE: do we have the right instruments? |
| Q37640271 | Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort |
| Q45237648 | Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus |
| Q40375245 | Distinct subtypes of myelitis in systemic lupus erythematosus |
| Q40723607 | Dr. Durcan, et al reply |
| Q72317535 | Dyspnea in ambulatory patients with SLE: prevalence, severity, and correlation with incremental exercise testing |
| Q33370141 | Early risk factors for pregnancy loss in lupus |
| Q47385774 | Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach |
| Q35229284 | Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort |
| Q33887820 | Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus |
| Q36747001 | Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis |
| Q49792194 | Effect of pregnancy on disease flares in patients with systemic lupus erythematosus |
| Q36245748 | Effect of pregnancy on serum cytokines in SLE patients |
| Q39556826 | Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility |
| Q36302240 | Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials |
| Q38388592 | Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy |
| Q44068958 | Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial |
| Q45081882 | Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus |
| Q37633396 | Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials |
| Q33731705 | Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial |
| Q28304807 | Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial |
| Q28660706 | Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study |
| Q42694406 | Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up |
| Q41418810 | Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study |
| Q30823425 | Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort |
| Q30828464 | Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus |
| Q71750940 | Elevation of maternal alpha-fetoprotein in systemic lupus erythematosus: a controlled study |
| Q37728822 | End-stage renal disease in African Americans with lupus nephritis is associated with APOL1 |
| Q33957431 | Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology |
| Q49684714 | Epidemiology of systemic lupus erythematosus: an update |
| Q33916234 | Epidemiology of the antiphospholipid antibody syndrome |
| Q37595993 | Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. |
| Q57420890 | Equivalence trials in SLE research: issues to consider |
| Q57332024 | Erratum: Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing |
| Q57329810 | Erratum: Genetic associations of LYN with systemic lupus erythematosus |
| Q36990282 | Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity |
| Q55083994 | Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. |
| Q46365642 | Estimating renal function in lupus nephritis: comparison of the Modification of Diet in Renal Disease and Cockcroft Gault equations |
| Q34187282 | European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies |
| Q37398821 | European genetic ancestry is associated with a decreased risk of lupus nephritis |
| Q37634162 | European population substructure correlates with systemic lupus erythematosus endophenotypes in North Americans of European descent |
| Q37335908 | European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus |
| Q33399089 | Evaluation of TRAF6 in a large multiancestral lupus cohort |
| Q72000650 | Evaluation of preterm delivery in a systemic lupus erythematosus pregnancy clinic |
| Q35022304 | Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort |
| Q35713249 | Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus |
| Q28165262 | Evidence-based management of thrombosis in the antiphospholipid antibody syndrome |
| Q46301201 | Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort |
| Q34227082 | Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy |
| Q33758208 | Factors associated with arterial vascular events in PROFILE: a Multiethnic Lupus Cohort |
| Q28608340 | Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort |
| Q46970545 | Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. |
| Q33800921 | Fcγ receptor IIIa single-nucleotide polymorphisms and haplotypes affect human IgG binding and are associated with lupus nephritis in African Americans |
| Q71539391 | Femoral head perfusion and composition: MR imaging and spectroscopic evaluation of patients with systemic lupus erythematosus and at risk for avascular necrosis |
| Q47873461 | Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort |
| Q34149215 | Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity |
| Q36595002 | Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups |
| Q35019514 | Fine-mapping and transethnic genotyping establish IL2/IL21 genetic association with lupus and localize this genetic effect to IL21 |
| Q46881605 | Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone |
| Q41941245 | Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience |
| Q78000544 | Frequency of the Fc gamma RIIIA-158F allele in African American patients with systemic lupus erythematosus |
| Q38813080 | Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab |
| Q35082379 | Genetic analyses of interferon pathway-related genes reveal multiple new loci associated with systemic lupus erythematosus |
| Q35210660 | Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study. |
| Q28273794 | Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. |
| Q37359966 | Genetic associations of LYN with systemic lupus erythematosus |
| Q36315896 | Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus |
| Q59543220 | Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans |
| Q36807470 | Genetic risk factors for thrombosis in systemic lupus erythematosus |
| Q46261093 | Genetic variation in the CRP promoter: association with systemic lupus erythematosus |
| Q28776419 | Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees |
| Q40532405 | Gestational weight gain in women with systemic lupus erythematosus |
| Q33703372 | Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes |
| Q47557472 | Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort |
| Q36529956 | H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus |
| Q43613798 | Hair product use in systemic lupus erythematosus. A case-control study |
| Q44915681 | Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study |
| Q38539802 | Healthcare costs of pregnancy in systemic lupus erythematosus: retrospective observational analysis from a US health claims database |
| Q33893388 | Hematopoietic stem cell transplantation for systemic lupus erythematosus |
| Q73766208 | Hereditary resistance to activated protein C: an uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies |
| Q50767841 | High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. |
| Q37418516 | High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups |
| Q34027812 | High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial |
| Q34986999 | High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases |
| Q44278522 | High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus |
| Q37161550 | High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus |
| Q73683618 | Hopkins Lupus Cohort. 1999 update |
| Q49827105 | Hopkins Lupus Cohort: assessment of treatment effects. |
| Q73069255 | Hopkins Lupus Pregnancy Center: 1987 to 1996 |
| Q37977272 | Hormone replacement and contraceptive therapy in autoimmune diseases |
| Q36240425 | Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence |
| Q33373145 | Hydroxychloroquine in lupus pregnancy |
| Q55507790 | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. |
| Q64949126 | Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America. |
| Q41109148 | Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. |
| Q41944990 | Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis |
| Q53798136 | Hydroxychloroquine-Induced Erythema Multiforme. |
| Q28253129 | IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus |
| Q33939594 | ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry |
| Q35877841 | Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study |
| Q34458811 | Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study |
| Q35489210 | Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study |
| Q35907785 | Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis |
| Q36783414 | IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. |
| Q77732658 | Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease |
| Q38883883 | Immunomodulators in SLE: Clinical evidence and immunologic actions |
| Q35135362 | Immunosuppressive drug use in pregnancy |
| Q30791606 | Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort |
| Q36360777 | Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations |
| Q48159097 | Impaired health status and the effect of pain and fatigue on functioning in clinical trial patients with systemic lupus erythematosus |
| Q37715948 | Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials |
| Q46660881 | Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups |
| Q36606667 | Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus |
| Q67965299 | Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort |
| Q38178109 | Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies |
| Q56907309 | Incorrect Values for Intractable and Cluster Headaches at Enrollment Shown in Figure 1 and Incorrect Prevalence of Headache at Ten Years in Text of the Article by Hanly et al (Arthritis Rheum, November 2013) |
| Q36394877 | Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients |
| Q39905586 | Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery-specific |
| Q74600355 | Infection in systemic lupus erythematosus |
| Q53035221 | Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. |
| Q36214319 | Interferon regulatory factor 1 and histone H4 acetylation in systemic lupus erythematosus |
| Q35125991 | Interferon regulatory factor 1 marks activated genes and can induce target gene expression in systemic lupus erythematosus |
| Q57329877 | Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans |
| Q33743791 | Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study |
| Q62111834 | Interferon-γ polymorphisms in systemic lupus erythematosus |
| Q33369397 | Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? |
| Q47796610 | Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus |
| Q33670694 | Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome |
| Q70041411 | Large intracranial arteritis with giant cells in systemic lupus erythematosus |
| Q39522524 | Laryngeal infection in lupus: report of nocardiosis and review of laryngeal involvement in lupus |
| Q34433298 | Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging |
| Q41028325 | Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study |
| Q34419948 | Long-term outcomes in lupus |
| Q47962680 | Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation |
| Q36759420 | Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy |
| Q35689999 | Longitudinal analysis of peripheral blood T cell receptor diversity in patients with systemic lupus erythematosus by next-generation sequencing |
| Q30873883 | Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus |
| Q35489690 | Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis |
| Q42323123 | Low Level of Haptoglobin in Lupus |
| Q90681087 | Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort |
| Q90435987 | Low frequency of flares during pregnancy and post-partum in stable lupus patients |
| Q36683387 | Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic lupus erythematosus |
| Q51767185 | Lung cancer in systemic lupus erythematosus. |
| Q55645538 | Lung cancer in systemic lupus erythematosus. |
| Q36060857 | Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression |
| Q37960250 | Lupus and pregnancy |
| Q40525187 | Lupus and pregnancy. |
| Q36472645 | Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results |
| Q33428578 | Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss |
| Q35505690 | Lupus enteritis: an uncommon manifestation of systemic lupus erythematosus |
| Q36373318 | Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort |
| Q73715368 | Lupus nephritis outcomes: health maintenance organizations compared to non-health maintenance organizations |
| Q34568717 | Lupus nephritis susceptibility loci in women with systemic lupus erythematosus |
| Q34881641 | Lupus risk variants in the PXK locus alter B-cell receptor internalization |
| Q37374458 | Lymphoma risk in systemic lupus: effects of disease activity versus treatment |
| Q93563095 | Lymphoma risk in systemic lupus: effects of treatment versus disease activity |
| Q34535634 | Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis |
| Q39762725 | Magnetic resonance imaging: a review of rheumatologic applications |
| Q28199914 | Management of antiphospholipid syndrome in pregnancy |
| Q38036105 | Management of pregnancy in systemic lupus erythematosus |
| Q37478567 | Management of the pregnant lupus patient. |
| Q44913899 | Managing lupus nephritis in pregnant women: comment on the article by Hahn et al. |
| Q27002228 | Managing lupus patients during pregnancy |
| Q62111864 | Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus |
| Q50533802 | Measures of disease activity, damage, and health status: the Hopkins Lupus Cohort experience. |
| Q55520929 | Measuring disease activity and severity in clinical trials and the clinic: same or different? |
| Q35156885 | Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial |
| Q34611257 | MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus |
| Q53181816 | Monitoring systemic lupus erythematosus in standard clinical care. |
| Q36892681 | Monocyte enhancers are highly altered in systemic lupus erythematosus |
| Q55060059 | Mononeuritis multiplex: the yield of evaluations for occult rheumatic diseases. |
| Q35797933 | Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study |
| Q46891297 | Morbidity of systemic lupus erythematosus: role of race and socioeconomic status |
| Q38467155 | Mortality in systemic lupus erythematosus |
| Q37498799 | Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus |
| Q72009136 | Musculoskeletal complications of systemic lupus erythematosus in the hopkins lupus cohort: An update |
| Q36697443 | Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years |
| Q46843590 | Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases |
| Q46818795 | Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis |
| Q44912547 | Neonatal lupus erythematosus syndrome: analysis of C4 allotypes and C4 genes in 18 families |
| Q72341177 | Neonatal lupus erythematosus. Report of serological and immunogenetic studies in twins discordant for congenital heart block |
| Q76381646 | Neurally mediated hypotension in systemic lupus erythematosus patients with fibromyalgia |
| Q35199278 | Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus |
| Q57330817 | Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study |
| Q48623904 | Neuropsychiatric systemic lupus erythematosus: miles to go before we sleep |
| Q52011027 | Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. |
| Q47136259 | Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study |
| Q37433355 | Non-lymphoma hematological malignancies in systemic lupus erythematosus |
| Q43181476 | Noncalcified coronary plaque in systemic lupus erythematosus |
| Q55176570 | Nonlymphoma hematological malignancies in systemic lupus erythematosus. |
| Q37356378 | Novel evidence-based systemic lupus erythematosus responder index |
| Q30409882 | Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus |
| Q59821020 | Oral abstracts 1: Spondyloarthropathies * O1. Detecting axial spondyloarthritis amongst primary care back pain referrals |
| Q53063788 | Oral candidiasis in systemic lupus erythematosus. |
| Q68901421 | Oral cimetidine improves the accuracy and precision of creatinine clearance in lupus nephritis |
| Q41472074 | Oral contraceptives and systemic lupus erythematosus |
| Q64893122 | Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. |
| Q78108630 | Outcome measures to be used in clinical trials in systemic lupus erythematosus |
| Q90178396 | PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21 |
| Q34946314 | PTPN22 association in systemic lupus erythematosus (SLE) with respect to individual ancestry and clinical sub-phenotypes |
| Q36788809 | PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome |
| Q37661946 | Pancreatitis in systemic lupus erythematosus: frequency and associated factors - a review of the Hopkins Lupus Cohort |
| Q44495281 | Pancreatitis in systemic lupus erythematosus: still in search of a mechanism |
| Q33498327 | Pathogenesis and treatment of the antiphospholipid antibody syndrome |
| Q73313572 | Patterns of disease activity in systemic lupus erythematosus |
| Q51302719 | Performance Characteristics of Commercial Immunoassays for the Detection of IgG and IgM Antibodies to β2 Glycoprotein I and an Initial Assessment of Newly Developed Reference Materials for Assay Calibration. |
| Q52652019 | Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin. |
| Q64075669 | Pericarditis in Lupus |
| Q42222884 | Peripheral neuropathies in systemic lupus erythematosus: clinical features, disease associations, and immunologic characteristics evaluated over a twenty-five-year study period |
| Q35596715 | Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus |
| Q51578946 | Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. |
| Q72142128 | Plasma thrombomodulin levels in women with systemic lupus erythematosus |
| Q74631269 | Postmenopausal estrogen replacement therapy and risk of developing systemic lupus erythematosus or discoid lupus |
| Q56341952 | Preconceptional Cardiovascular Health and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus |
| Q35977256 | Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies |
| Q40973492 | Predictors of Incident Seizure in Systemic Lupus Erythematosus |
| Q37420173 | Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study |
| Q46315593 | Predictors of carotid atherosclerosis in systemic lupus erythematosus. |
| Q45740730 | Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort |
| Q46144242 | Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus |
| Q44603897 | Predictors of incident depression in systemic lupus erythematosus |
| Q47100353 | Predictors of incident proteinuria among patients with SLE. |
| Q36434629 | Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort |
| Q59808159 | Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort |
| Q35639129 | Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus |
| Q37090064 | Predictors of self-reported health-related quality of life in systemic lupus erythematosus |
| Q38468220 | Predictors of survival in systemic lupus erythematosus |
| Q36761678 | Prednisone, lupus activity, and permanent organ damage |
| Q36475603 | Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. |
| Q35018126 | Preferential binding to Elk-1 by SLE-associated IL10 risk allele upregulates IL10 expression |
| Q37811609 | Pregnancy and reproduction in autoimmune rheumatic diseases |
| Q46339836 | Prevalence of a mutation causing C2 deficiency in systemic lupus erythematosus. |
| Q40680218 | Prevalence of cerebral microemboli in systemic lupus erythematosus: transcranial Doppler. |
| Q46771656 | Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study |
| Q36511541 | Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis |
| Q38214067 | Prevention and management of co-morbidities in SLE. |
| Q37690404 | Progression of coronary artery atherosclerosis in rheumatoid arthritis: comparison with participants from the Multi-Ethnic Study of Atherosclerosis |
| Q40459284 | Progression of noncalcified and calcified coronary plaque by CT angiography in SLE. |
| Q34087831 | Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus |
| Q58093032 | Psychosis in Systemic Lupus Erythematosus |
| Q92603398 | Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis |
| Q69703121 | Pulmonary hypertension in systemic lupus erythematosus |
| Q37768381 | Quality-of-life measurements versus disease activity in systemic lupus erythematosus |
| Q54965930 | Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort. |
| Q57330901 | Race/ethnicity and cancer occurrence in systemic lupus erythematosus |
| Q40824882 | Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains |
| Q39536444 | Randomized, double-blind, placebo-controlled study of the treatment of the painful shoulder |
| Q73592313 | Recommendations for exogenous estrogen to prevent glucocorticoid-induced osteoporosis in premenopausal women with oligo- or amenorrhea: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoi |
| Q40608248 | Remission in systemic lupus erythematosus: durable remission is rare |
| Q50710808 | Renal biopsy in lupus patients with low levels of proteinuria. |
| Q37330829 | Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population |
| Q56379473 | Response to: 'Postpartum breastfeeding status' by Betzold |
| Q44890333 | Response to: 'Remission in SLE: the duration depends on multiple factors, including the definition' by Doria et al. |
| Q46254756 | Response to: 'belimumab and the measurement of fatigue' by Mazzoni |
| Q36142461 | Review of classification criteria for systemic lupus erythematosus |
| Q33838212 | Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes |
| Q67586359 | Risk factors for coronary artery disease in patients with systemic lupus erythematosus |
| Q73218948 | Risk factors for osteonecrosis in systemic lupus erythematosus |
| Q35899141 | Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis |
| Q37226689 | SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus |
| Q51113113 | SLE patients with renal damage incur higher health care costs. |
| Q36775795 | SLE-key(®) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP(®). |
| Q37272264 | Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices |
| Q30580226 | Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus |
| Q36683373 | Seasonal variation in the activity of systemic lupus erythematosus |
| Q36307429 | Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study |
| Q36709328 | Semiquantified noncalcified coronary plaque in systemic lupus erythematosus |
| Q46082712 | Serial assessment of glomerular filtration rate in lupus nephropathy |
| Q71906026 | Serum complement determinations in patients with quiescent systemic lupus erythematosus |
| Q46798854 | Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus |
| Q36307414 | Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study |
| Q36844513 | Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study |
| Q36165313 | Significance of Lipid-Derived Reactive Aldehyde-Specific Immune Complexes in Systemic Lupus Erythematosus |
| Q48262185 | Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus |
| Q38798999 | Socioeconomic Status Contributes to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes among Women with Systemic Lupus Erythematosus |
| Q36676990 | Socioeconomic status in systemic lupus erythematosus |
| Q46821105 | Soluble CD154 is not associated with atherosclerosis in systemic lupus erythematosus |
| Q53497854 | Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. |
| Q90820946 | Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus |
| Q33339386 | Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus |
| Q39095546 | Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients |
| Q37722431 | Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus |
| Q53773089 | Systemic Lupus Erythematosus and Pregnancy. |
| Q41219739 | Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. |
| Q72353000 | Systemic lupus erythematosus and pregnancy |
| Q37951280 | Systemic lupus erythematosus one disease or many? |
| Q36399375 | Systemic lupus erythematosus: 2006 update |
| Q34158253 | Systemic lupus erythematosus: women's health issues. |
| Q57330769 | Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response |
| Q50647508 | Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. |
| Q72725334 | T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity |
| Q58004012 | Testing strategies for diagnosing lupus anticoagulant: Decision analysis |
| Q43615873 | The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary |
| Q62111856 | The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus |
| Q35167259 | The Hopkins Lupus Pregnancy Center: 1987–1991 Update |
| Q36820975 | The Hopkins Lupus Pregnancy Center: ten key issues in management |
| Q34764041 | The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share |
| Q40283637 | The Role of MicroRNAs and Human Epidermal Growth Factor Receptor 2 in Proliferative Lupus Nephritis |
| Q28538471 | The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs |
| Q73471436 | The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison |
| Q35867539 | The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus |
| Q36127922 | The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA. |
| Q67865324 | The automated modified Russell viper venom time test for the lupus anticoagulant |
| Q68136488 | The clinical syndrome associated with antiphospholipid antibodies |
| Q47839146 | The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus |
| Q40974327 | The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus |
| Q46557882 | The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial |
| Q46777706 | The effect of race on incidence and clinical course in systemic lupus erythematosus: The Hopkins Lupus Cohort. |
| Q74300461 | The egg and I: preserving fertility in systemic lupus erythematosus |
| Q37082037 | The frequency and outcome of lupus nephritis: results from an international inception cohort study |
| Q39289964 | The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level |
| Q92826945 | The immune cell landscape in kidneys of patients with lupus nephritis |
| Q46345098 | The impact of increased lupus activity on obstetric outcomes |
| Q46561334 | The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort |
| Q33701388 | The lupus family registry and repository |
| Q34038096 | The non-muscle Myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans |
| Q62111857 | The polymorphic CYP17 allele is not found with increased frequency in systemic lupus erythematosus |
| Q40237986 | The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients |
| Q57331048 | The rate and pattern of organ damage in late onset systemic lupus erythematosus |
| Q28212163 | The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study |
| Q33420116 | The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features |
| Q73343774 | The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus |
| Q21296846 | The role of genetic variation near interferon-kappa in systemic lupus erythematosus |
| Q50758139 | The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being. |
| Q40760514 | The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group |
| Q35741943 | Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus |
| Q71500994 | Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective |
| Q28766942 | Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort |
| Q37455235 | Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort |
| Q73324347 | Tissue factor activity in patients with systemic lupus erythematosus: association with disease activity |
| Q48596899 | Toward optimal health: Michelle Petri, M.D. discusses advances in lupus management in women with Jodi R. Godfrey (Contributing Editor). |
| Q38676110 | Transancestral mapping and genetic load in systemic lupus erythematosus |
| Q38149851 | Transient ischemic attack and stroke in systemic lupus erythematosus |
| Q74685115 | Treatment of systemic lupus erythematosus: an update |
| Q34108983 | Treatment of the antiphospholipid antibody syndrome: progress in the last five years? |
| Q37693206 | Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription |
| Q34171558 | Two major autoantibody clusters in systemic lupus erythematosus |
| Q50667908 | Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group. |
| Q27005906 | Unmet medical needs in systemic lupus erythematosus |
| Q36713542 | Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis |
| Q43300209 | Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis |
| Q53311622 | Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus. |
| Q45004730 | Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. |
| Q91502625 | Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen |
| Q37803363 | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients |
| Q36709341 | Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus |
| Q68086089 | Validity and reliability of lupus activity measures in the routine clinic setting |
| Q33723441 | Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome |
| Q24633276 | Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry |
| Q37324934 | Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus |
| Q36303706 | Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries |
| Q37234685 | Vitamin D deficiency does not predict progression of coronary artery calcium, carotid intima-media thickness or high-sensitivity C-reactive protein in systemic lupus erythematosus |
| Q36983027 | Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio |
| Q33557656 | Wegener's granulomatosis: isolated involvement of the trachea and larynx |
| Q38920435 | Why targeted therapies are necessary for systemic lupus erythematosus |
Search more.